{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:31:00Z","timestamp":1759969860917,"version":"build-2065373602"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.maturitas.2005.10.004","type":"journal-article","created":{"date-parts":[[2005,12,22]],"date-time":"2005-12-22T08:30:20Z","timestamp":1135240220000},"page":"154-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Which progestogen is more likely to increase the risk of fatal myocardial infarction: A combination of epidemiological and trial evidence"],"prefix":"10.1016","volume":"54","author":[{"given":"Farook","family":"Al-Azzawi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2005.10.004_bib1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2005.10.004_bib2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.7326\/0003-4819-127-12-199712150-00007","article-title":"Personal use of postmenopausal hormone replacement therapy by women physicians in the United States","volume":"127","author":"McNagny","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.maturitas.2005.10.004_bib3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0378-5122(97)00076-5","article-title":"Improving compliance with hormonal replacement therapy in primary osteoporosis prevention","volume":"28","author":"Vestergaard","year":"1997","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2005.10.004_bib4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa030808","article-title":"Estrogen plus progestin and the risk of coronary heart disease","volume":"349","author":"Manson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2005.10.004_bib5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7326\/0003-4819-89-2-157","article-title":"Menopause and coronary heart disease. The Framingham Study","volume":"89","author":"Gordon","year":"1978","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.maturitas.2005.10.004_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0021-9150(93)90225-J","article-title":"Influence of age and menopause on serum lipids and lipoproteins in healthy women","volume":"98","author":"Stevenson","year":"1993","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.maturitas.2005.10.004_bib7","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/0002-8703(88)90063-4","article-title":"Postmenopausal use of estrogen and occlusion of coronary arteries","volume":"115","author":"Gruchow","year":"1988","journal-title":"Am Heart J"},{"key":"10.1016\/j.maturitas.2005.10.004_bib8","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1210\/jcem-73-5-925","article-title":"Clinical review 27: effects of hormonal replacement on lipids and lipoproteins in postmenopausal women","volume":"73","author":"Lobo","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2005.10.004_bib9","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJM199110243251702","article-title":"Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins","volume":"325","author":"Walsh","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2005.10.004_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0009-8981(86)90047-1","article-title":"Lipoprotein and apoprotein levels in postmenopausal women during treatment with norethisterone","volume":"159","author":"Farish","year":"1986","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.maturitas.2005.10.004_bib11","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJM198911093211907","article-title":"High-density lipoprotein\u2014the clinical implications of recent studies","volume":"321","author":"Gordon","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2005.10.004_bib12","first-page":"19","article-title":"Effect of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteins","volume":"83","author":"Marsh","year":"1994","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2005.10.004_bib13","first-page":"140S","article-title":"Metabolic effects of estrogens and progestins","volume":"62","author":"LaRosa","year":"1994","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2005.10.004_bib14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1161\/01.ATV.14.2.275","article-title":"Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women","volume":"14","author":"Kim","year":"1994","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.maturitas.2005.10.004_bib15","first-page":"568","article-title":"Changes in the lipoprotein profile in postmenopausal women receiving hormone replacement therapy. Effects of natural and synthetic progesterone","volume":"43","author":"Chen","year":"1998","journal-title":"J Reprod Med"},{"key":"10.1016\/j.maturitas.2005.10.004_bib16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0002-9378(95)90174-4","article-title":"A prospective 2-year study of progestin given alone in postmenopausal women: effect on lipid and metabolic parameters","volume":"173","author":"Tremollieres","year":"1995","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2005.10.004_bib17","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1161\/01.CIR.80.4.1070","article-title":"The cholesterol controversy is over. Why did it take so long?","volume":"80","author":"Steinberg","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.maturitas.2005.10.004_bib18","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2005.10.004_bib19","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2005.10.004_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2005.10.004_bib21","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1053\/euhj.1998.1243","article-title":"Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention","volume":"19","author":"Wood","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1016\/j.maturitas.2005.10.004_bib22","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/0002-9378(88)90198-6","article-title":"Effects of estrogen dose and smoking on lipid and lipoprotein levels in postmenopausal women","volume":"158","author":"Krauss","year":"1988","journal-title":"Am J Obstetr Gynecol"},{"key":"10.1016\/j.maturitas.2005.10.004_bib23","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0022-2275(20)39173-2","article-title":"Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study","volume":"35","author":"Schaefer","year":"1994","journal-title":"J Lipid Res"},{"key":"10.1016\/j.maturitas.2005.10.004_bib24","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1093\/clinchem\/43.12.2364","article-title":"Apolipoprotein B and AI distributions in the United States, 1988\u20131991: results of the National Health and Nutrition Examination Survey III (NHANES III)","volume":"43","author":"Bachorik","year":"1997","journal-title":"Clin Chem"},{"key":"10.1016\/j.maturitas.2005.10.004_bib25","first-page":"409","article-title":"Reference values of plasma apolipoproteins A-I and B, and association with nonlipid risk factors in the populations of two Canadian provinces: Quebec and Saskatchewan. Canadian Heart Health Surveys Research Group","volume":"15","author":"Connelly","year":"1999","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.maturitas.2005.10.004_bib26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1161\/01.ATV.21.4.481","article-title":"HDL and the inflammatory response induced by LDL-derived oxidized phospholipids","volume":"21","author":"Navab","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.maturitas.2005.10.004_bib27","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1161\/01.CIR.0000103624.14436.4B","article-title":"Inflammatory\/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment","volume":"108","author":"Ansell","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.maturitas.2005.10.004_bib28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI200421109","article-title":"Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease","volume":"114","author":"Zheng","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.maturitas.2005.10.004_bib29","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0022-2275(20)33462-3","article-title":"Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3","volume":"41","author":"Navab","year":"2000","journal-title":"J Lipid Res"},{"key":"10.1016\/j.maturitas.2005.10.004_bib30","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0022-2275(20)33461-1","article-title":"Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1","volume":"41","author":"Navab","year":"2000","journal-title":"J Lipid Res"},{"key":"10.1016\/j.maturitas.2005.10.004_bib31","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/hc0302.103711","article-title":"Oral administration of an Apo A-I mimetic Peptide synthesized from d-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol","volume":"105","author":"Navab","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.maturitas.2005.10.004_bib32","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1161\/01.CIR.0000134275.90823.87","article-title":"Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoproteinmediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice","volume":"109","author":"Navab","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.maturitas.2005.10.004_bib33","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1161\/01.ATV.10.5.668","article-title":"Does measurement of apolipoprotein B have a place in cholesterol management?","volume":"10","author":"Vega","year":"1990","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.maturitas.2005.10.004_bib34","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/clinchem\/42.4.489","article-title":"Measurement of apoproteins: time to improve the diagnosis and treatment of the atherogenic dyslipoproteinemias","volume":"42","author":"Sniderman","year":"1996","journal-title":"Clin Chem"},{"key":"10.1016\/j.maturitas.2005.10.004_bib35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0140-6736(94)90814-1","article-title":"Apolipoproteins and ischaemic heart disease: implications for screening","volume":"343","author":"Wald","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2005.10.004_bib36","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1161\/01.CIR.94.3.273","article-title":"Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a 5-year follow-up of men in the Quebec cardiovascular study","volume":"94","author":"Lamarche","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.maturitas.2005.10.004_bib37","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1161\/01.CIR.89.5.1967","article-title":"Plasma apolipoprotein concentrations in young adults with a parental history of premature coronary heart disease and in control subjects. The EARS Study. European Atherosclerosis Research Study","volume":"89","author":"Rosseneu","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.maturitas.2005.10.004_bib38","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/clinchem\/43.8.1310","article-title":"Counterpoint: to (measure apo) B or not to (measure apo) B: a critique of modern medical decision-making","volume":"43","author":"Sniderman","year":"1997","journal-title":"Clin Chem"},{"key":"10.1016\/j.maturitas.2005.10.004_bib39","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)12663-3","article-title":"Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment","volume":"361","author":"Sniderman","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2005.10.004_bib40","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/clinchem\/37.10.1676","article-title":"International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B","volume":"37","author":"Marcovina","year":"1991","journal-title":"Clin Chem"},{"key":"10.1016\/j.maturitas.2005.10.004_bib41","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/clinchem\/38.5.658","article-title":"International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. II. Evaluation and selection of candidate reference materials","volume":"38","author":"Albers","year":"1992","journal-title":"Clin Chem"},{"key":"10.1016\/j.maturitas.2005.10.004_bib42","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/clinchem\/39.5.773","article-title":"International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material","volume":"39","author":"Marcovina","year":"1993","journal-title":"Clin Chem"},{"key":"10.1016\/j.maturitas.2005.10.004_bib43","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/clinchem\/40.4.586","article-title":"International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material","volume":"40","author":"Marcovina","year":"1994","journal-title":"Clin Chem"},{"key":"10.1016\/j.maturitas.2005.10.004_bib44","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/clinchem\/36.4.591","article-title":"Immunological assays of apolipoproteins in plasma: methods and instrumentation","volume":"36","author":"Labeur","year":"1990","journal-title":"Clin Chem"},{"key":"10.1016\/j.maturitas.2005.10.004_bib45","series-title":"Laboratory measurement of lipids, lipoproteins and apolipoproteins","first-page":"141","article-title":"Clinical significance and measurement of apolipoproteins A-1 and B","author":"Stein","year":"1994"},{"key":"10.1016\/j.maturitas.2005.10.004_bib46","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(01)07098-2","article-title":"High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study","volume":"358","author":"Walldius","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2005.10.004_bib47","first-page":"205","article-title":"Routine diagnostic testing for apoA-I, apo-B, Lp(a), and LDL cholesterol in clinical laboratories","volume":"7","author":"Schaefer","year":"1994","journal-title":"Clin Lab Sci"},{"key":"10.1016\/j.maturitas.2005.10.004_bib48","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/oxfordjournals.eurheartj.a060937","article-title":"Relationship between HDL-cholesterol and apolipoprotein A1 and the severity of coronary artery disease","volume":"16","author":"Garfagnini","year":"1995","journal-title":"Eur Heart J"},{"key":"10.1016\/j.maturitas.2005.10.004_bib49","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/01.ATV.18.7.1101","article-title":"Apolipoprotein B and coronary artery disease in women: a cross-sectional study in women undergoing their first coronary angiography","volume":"18","author":"Westerveld","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.maturitas.2005.10.004_bib50","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0021-9150(00)00528-1","article-title":"Coronary artery disease in patients at low risk-apolipoprotein AI as an independent risk factor","volume":"155","author":"Francis","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.maturitas.2005.10.004_bib51","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3109\/09513599909167574","article-title":"The pharmacological profile of a novel norpregnance progestin (trimegestone)","volume":"13","author":"Philibert","year":"1999","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.maturitas.2005.10.004_bib52","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1080\/13697130400001364","article-title":"Randomized trial of effects of estradiol in combination with either norethisterone acetate or trimegestone on lipids and lipoproteins in postmenopausal women","volume":"7","author":"Al-Azzawi","year":"2004","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2005.10.004_bib53","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/cmt.4.4.343.354","article-title":"Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate","volume":"4","author":"Al-Azzawi","year":"2001","journal-title":"Climacteric"},{"year":"1997","series-title":"Analysis of incomplete multivariate data","author":"Schafer","key":"10.1016\/j.maturitas.2005.10.004_bib54"},{"key":"10.1016\/j.maturitas.2005.10.004_bib55","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/clinchem\/44.1.134","article-title":"Plasma apolipoproteins A-I and B in survivors of myocardial infarction and in a control group","volume":"44","author":"Graziani","year":"1998","journal-title":"Clin Chem"},{"key":"10.1016\/j.maturitas.2005.10.004_bib56","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1161\/01.CIR.102.16.1886","article-title":"VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial","volume":"102","author":"Sacks","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.maturitas.2005.10.004_bib57","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/01.ATV.20.11.2408","article-title":"Apolipoprotein concentrations during treatment and recurrent coronary artery disease events","volume":"20","author":"van Lennep","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.maturitas.2005.10.004_bib58","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1016\/S0021-9258(18)49957-7","article-title":"Interaction of free apolipoproteins with macrophages. Formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol","volume":"266","author":"Hara","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.maturitas.2005.10.004_bib59","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(99)07026-9","article-title":"Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux","volume":"354","author":"Marcil","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2005.10.004_bib60","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/11921","article-title":"Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1","volume":"22","author":"Rust","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.maturitas.2005.10.004_bib61","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/S0022-2275(20)32356-7","article-title":"Involvement of caveolin-1 in cholesterol enrichment of high density lipoprotein during its assembly by apolipoprotein and THP-1 cells","volume":"41","author":"Arakawa","year":"2000","journal-title":"J Lipid Res"},{"key":"10.1016\/j.maturitas.2005.10.004_bib62","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1073\/pnas.94.8.3753","article-title":"Caveolin mRNA levels are up-regulated by free cholesterol and down-regulated by oxysterols in fibroblast monolayers","volume":"94","author":"Fielding","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.maturitas.2005.10.004_bib63","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1388-1981(01)00124-X","article-title":"Progesterone inhibits apolipoprotein-mediated cellular lipid release: a putative mechanism for the decrease of high-density lipoprotein","volume":"1532","author":"Kojima","year":"2001","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.maturitas.2005.10.004_bib64","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037851220500263X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037851220500263X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:41:41Z","timestamp":1759912901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S037851220500263X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S037851220500263X"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2005.10.004","relation":{},"ISSN":["0378-5122"],"issn-type":[{"type":"print","value":"0378-5122"}],"subject":[],"published":{"date-parts":[[2006,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Which progestogen is more likely to increase the risk of fatal myocardial infarction: A combination of epidemiological and trial evidence","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2005.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}